伊拉克2型糖尿病患者因新冠肺炎住院后的状况

Q3 Medicine
Hiba S Ahmed, Haylim N Abud, Hind S Ahmed
{"title":"伊拉克2型糖尿病患者因新冠肺炎住院后的状况","authors":"Hiba S Ahmed, Haylim N Abud, Hind S Ahmed","doi":"10.1177/10932607241304947","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The coronavirus-19 (COVID-19) pandemic, triggered by the severe acute respiratory syndrome coronavirus 2, has affected over 100 million people and killed around 2 million individuals. One of the most common chronic illnesses in the world is diabetes, which greatly raises the risk of hospitalization and death for COVID-19 patients.</p><p><strong>Objective: </strong>This study aims to analyze the novel coronavirus's general characteristics and shed light on COVID-19 and its management in diabetic individuals by measuring some metabolic and inflammatory factors in type 2 diabetic patients with and without COVID-19.</p><p><strong>Methods: </strong>One hundred Iraqi patients with type 2 diabetes mellitus (T2DM) were enrolled in the current study; 50 had COVID-19 with the Omicron variant, and 50 weren't. The diagnosis was designed by the consultant medical staff at the clinic. Eligible individuals had a positive nasal swab for reverse transcription polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 infection. They were compared with 50 healthy individuals as a control group. Every participant's anthropometric and clinical features were measured. The study includes the study groups' glycemic, lipid profile, serum urea, and C-reactive protein (CRP) measurements.</p><p><strong>Results: </strong>There were remarkable rises (<i>p </i>< 0.05) in fasting and random blood glucose, serum lipid, and urea levels in diabetic patients with COVID-19 compared to those without COVID-19 and the control group. Also, a significant elevation (<i>p </i>= 0.01) was found in fasting serum insulin among diabetic patients with COVID-19 as compared to those without COVID-19 and the control group (32.75 ± 8.63 vs. 25.82 ± 3.50 and 10.65 ± 1.12) µU/L, respectively. Serum CRP levels significantly increased (<i>p </i>= 0.0001) in diabetic patients with COVID-19 compared to other groups.</p><p><strong>Conclusion: </strong>Hyperglycemia, hyperinsulinemia, and dyslipidemia resulting from cytokine storm significantly increased the risk of hospitalization and death among coronavirus disease-19 patients. It has been concluded that T2DM reliably predicts morbidity among COVID-19 patients presenting with symptoms suggestive of severe hyperglycemia. The results also show the temporary and reversible deficiency in insulin secretion associated with severe acute respiratory syndrome coronavirus-2 infection. Consequently, it is recommended to examine variables of insulin sensitivity and pancreatic islet activity among patients with COVID-19 who have a history of diabetes.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"10932607241304947"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"State of type 2 diabetic Iraqi patients after hospitalization for COVID-19.\",\"authors\":\"Hiba S Ahmed, Haylim N Abud, Hind S Ahmed\",\"doi\":\"10.1177/10932607241304947\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The coronavirus-19 (COVID-19) pandemic, triggered by the severe acute respiratory syndrome coronavirus 2, has affected over 100 million people and killed around 2 million individuals. One of the most common chronic illnesses in the world is diabetes, which greatly raises the risk of hospitalization and death for COVID-19 patients.</p><p><strong>Objective: </strong>This study aims to analyze the novel coronavirus's general characteristics and shed light on COVID-19 and its management in diabetic individuals by measuring some metabolic and inflammatory factors in type 2 diabetic patients with and without COVID-19.</p><p><strong>Methods: </strong>One hundred Iraqi patients with type 2 diabetes mellitus (T2DM) were enrolled in the current study; 50 had COVID-19 with the Omicron variant, and 50 weren't. The diagnosis was designed by the consultant medical staff at the clinic. Eligible individuals had a positive nasal swab for reverse transcription polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 infection. They were compared with 50 healthy individuals as a control group. Every participant's anthropometric and clinical features were measured. The study includes the study groups' glycemic, lipid profile, serum urea, and C-reactive protein (CRP) measurements.</p><p><strong>Results: </strong>There were remarkable rises (<i>p </i>< 0.05) in fasting and random blood glucose, serum lipid, and urea levels in diabetic patients with COVID-19 compared to those without COVID-19 and the control group. Also, a significant elevation (<i>p </i>= 0.01) was found in fasting serum insulin among diabetic patients with COVID-19 as compared to those without COVID-19 and the control group (32.75 ± 8.63 vs. 25.82 ± 3.50 and 10.65 ± 1.12) µU/L, respectively. Serum CRP levels significantly increased (<i>p </i>= 0.0001) in diabetic patients with COVID-19 compared to other groups.</p><p><strong>Conclusion: </strong>Hyperglycemia, hyperinsulinemia, and dyslipidemia resulting from cytokine storm significantly increased the risk of hospitalization and death among coronavirus disease-19 patients. It has been concluded that T2DM reliably predicts morbidity among COVID-19 patients presenting with symptoms suggestive of severe hyperglycemia. The results also show the temporary and reversible deficiency in insulin secretion associated with severe acute respiratory syndrome coronavirus-2 infection. Consequently, it is recommended to examine variables of insulin sensitivity and pancreatic islet activity among patients with COVID-19 who have a history of diabetes.</p>\",\"PeriodicalId\":53564,\"journal\":{\"name\":\"Human Antibodies\",\"volume\":\" \",\"pages\":\"10932607241304947\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Antibodies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/10932607241304947\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/10932607241304947","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:由严重急性呼吸系统综合征冠状病毒2引发的冠状病毒-19 (COVID-19)大流行已影响1亿多人,造成约200万人死亡。糖尿病是世界上最常见的慢性疾病之一,它大大增加了COVID-19患者住院和死亡的风险。目的:通过检测2型糖尿病合并和不合并新冠肺炎患者的代谢和炎症因子,分析新型冠状病毒的一般特征,为糖尿病患者的新冠肺炎及其治疗提供参考。方法:100例伊拉克2型糖尿病(T2DM)患者加入本研究;50人感染了带有欧米克隆变异的COVID-19, 50人没有。诊断是由诊所的顾问医务人员设计的。符合条件的患者鼻拭子检测结果为严重急性呼吸综合征冠状病毒2型感染逆转录聚合酶链反应阳性。他们与50名健康人作为对照组进行了比较。测量每位参与者的人体测量和临床特征。该研究包括研究组的血糖、血脂、血清尿素和c反应蛋白(CRP)测量。结果:糖尿病合并新冠肺炎患者空腹血清胰岛素水平较未合并新冠肺炎患者和对照组显著升高(32.75±8.63∶25.82±3.50∶10.65±1.12)µU/L,差异有统计学意义(p p = 0.01)。与其他组相比,合并COVID-19的糖尿病患者血清CRP水平显著升高(p = 0.0001)。结论:细胞因子风暴导致的高血糖、高胰岛素血症和血脂异常显著增加了冠状病毒病-19患者住院和死亡的风险。T2DM可以可靠地预测出现严重高血糖症状的COVID-19患者的发病率。研究结果还显示,胰岛素分泌暂时和可逆的不足与严重急性呼吸综合征冠状病毒-2感染有关。因此,建议检查有糖尿病史的COVID-19患者的胰岛素敏感性和胰岛活性变量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
State of type 2 diabetic Iraqi patients after hospitalization for COVID-19.

Background: The coronavirus-19 (COVID-19) pandemic, triggered by the severe acute respiratory syndrome coronavirus 2, has affected over 100 million people and killed around 2 million individuals. One of the most common chronic illnesses in the world is diabetes, which greatly raises the risk of hospitalization and death for COVID-19 patients.

Objective: This study aims to analyze the novel coronavirus's general characteristics and shed light on COVID-19 and its management in diabetic individuals by measuring some metabolic and inflammatory factors in type 2 diabetic patients with and without COVID-19.

Methods: One hundred Iraqi patients with type 2 diabetes mellitus (T2DM) were enrolled in the current study; 50 had COVID-19 with the Omicron variant, and 50 weren't. The diagnosis was designed by the consultant medical staff at the clinic. Eligible individuals had a positive nasal swab for reverse transcription polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 infection. They were compared with 50 healthy individuals as a control group. Every participant's anthropometric and clinical features were measured. The study includes the study groups' glycemic, lipid profile, serum urea, and C-reactive protein (CRP) measurements.

Results: There were remarkable rises (p < 0.05) in fasting and random blood glucose, serum lipid, and urea levels in diabetic patients with COVID-19 compared to those without COVID-19 and the control group. Also, a significant elevation (p = 0.01) was found in fasting serum insulin among diabetic patients with COVID-19 as compared to those without COVID-19 and the control group (32.75 ± 8.63 vs. 25.82 ± 3.50 and 10.65 ± 1.12) µU/L, respectively. Serum CRP levels significantly increased (p = 0.0001) in diabetic patients with COVID-19 compared to other groups.

Conclusion: Hyperglycemia, hyperinsulinemia, and dyslipidemia resulting from cytokine storm significantly increased the risk of hospitalization and death among coronavirus disease-19 patients. It has been concluded that T2DM reliably predicts morbidity among COVID-19 patients presenting with symptoms suggestive of severe hyperglycemia. The results also show the temporary and reversible deficiency in insulin secretion associated with severe acute respiratory syndrome coronavirus-2 infection. Consequently, it is recommended to examine variables of insulin sensitivity and pancreatic islet activity among patients with COVID-19 who have a history of diabetes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Human Antibodies
Human Antibodies Medicine-Immunology and Allergy
CiteScore
3.50
自引率
0.00%
发文量
27
期刊介绍: Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology under a single, cohesive theme. This includes fundamental research, applied science and clinical applications. Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors. Immunoregulatory molecules, including T cell hybridomas, will also be featured.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信